Form 4: Recursion Pharmaceuticals Director Dean Y. Li Reports Acquisition of Shares

Director Dean Y. Li reports the acquisition of shares in Recursion Pharmaceuticals, along with adjustments to beneficial ownership.

Summary

• Dean Y. Li, a director at Recursion Pharmaceuticals, reported a transaction on April 1, 2025.
• Li acquired 2,268 shares of Class A Common Stock at $0 per share under the Issuer's Outside Director Compensation Policy.
• Following the transaction, Li directly owns 79,618 shares of Class A Common Stock.
• Li also has indirect ownership through several trusts: 1,422,048 shares via the Dean Li and Ruth Li Revocable Trust, 1,269,796 shares via the Dean Y. Li GRAT, and 421,000 shares via the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a transaction. The acquisition of shares by a director is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership positions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Recursion Pharmaceuticals, Director, Dean Y. Li, Beneficial Ownership, Form 4, Share Acquisition, RXRX, Outside Director Compensation Policy